The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

These medications have been shown to reduce the risk of heart attack and stroke. If you have liver disease or damage, your doctor may recommend a lower dose of statins or prescribe a different ...

Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

The drugs treat diabetes, heart failure, arthritis and more ... After narrowing down a list of drugs eligible for negotiation under the parameters, Medicare further narrowed down the list to ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

Alnylam Pharmaceuticals' shares rose more than 10% on Friday after the drugmaker secured U.S. approval for its heart disease drug, setting the stage for the 23-year-old biotech's next phase of growth.